Siemens Molecular Imaging

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Siemens Molecular Imaging sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Siemens Molecular Imaging: 9 sponsored US clinical trials, none currently recruiting.

Siemens Molecular Imaging sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Brain Cancer, with 1 trials.

Top-decile sponsor footprint

Siemens Molecular Imaging ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

TERMINATED Phase 2

[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis

NCT01602471
TERMINATED Phase 1

Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

NCT01362712
COMPLETED Phase 2

Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

NCT00988936
COMPLETED Early Phase 1

Exploratory and Safety Study of [F-18]W372

NCT00954369
COMPLETED Early Phase 1

An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037

NCT00884520
COMPLETED NA

A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation

NCT00847509
COMPLETED Early Phase 1

Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5

NCT00743353
COMPLETED Early Phase 1

An Exploratory, Open Label, Single Center Study of [F-18]HX4

NCT00606424
COMPLETED Phase 1

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

NCT00553748

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Therapeutic Areas

Brain Cancer 1

How the Siemens Molecular Imaging early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Brain Cancer (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Siemens Molecular Imaging: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Siemens Molecular Imaging sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Siemens Molecular Imaging4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Siemens Molecular Imaging sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Siemens Molecular Imaging sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Siemens Molecular Imaging page

9 registered trials is a research-attention snapshot, not an endorsement of Siemens Molecular Imaging or any single study.

  • None of Siemens Molecular Imaging's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Brain Cancer is the condition Siemens Molecular Imaging studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Siemens Molecular Imaging pipeline card: 9 registered trials from official public datasets.Report a data error.